UNLABELLED: The efficacy of probiotics supplementation in children undergoing Helicobacter pylori (H. pylori) eradication therapy remains controversial. This study aimed to meta-analyze whether probiotics supplementation in triple therapy could improve H. pylori eradication rates and reduce therapy-related side effects in children. Electronic databases PubMed and Embase were searched to identify all randomized controlled trials in pediatric patients comparing probiotics supplementation with placebo or no extra intervention in H. pylori eradication therapy. Two authors independently extracted the data. Results were expressed as odds ratios (ORs) and accompanying 95 % confidence intervals (CIs). Stata version 12.0 was used to perform all statistical analyses. Seven studies consisting of 508 pediatric patients were included in our study. The pooled ORs (studies n = 7) of eradication rates by intention-to-treat and per-protocol analysis in the probiotics group versus the control group were 1.96 (95 % CI 1.28-3.02) and 2.25 (95 % CI 1.41-3.57), respectively. The pooled OR (studies n = 5) of incidence of total side effects was 0.32 (95 % CI 0.13-0.79), with significant heterogeneity observed (I (2) = 71.9 %). CONCLUSION: Probiotics supplementation in triple therapy for H. pylori infection may have beneficial effects on eradication and therapy-related side effects, particularly diarrhea, in children.
UNLABELLED: The efficacy of probiotics supplementation in children undergoing Helicobacter pylori (H. pylori) eradication therapy remains controversial. This study aimed to meta-analyze whether probiotics supplementation in triple therapy could improve H. pylori eradication rates and reduce therapy-related side effects in children. Electronic databases PubMed and Embase were searched to identify all randomized controlled trials in pediatric patients comparing probiotics supplementation with placebo or no extra intervention in H. pylori eradication therapy. Two authors independently extracted the data. Results were expressed as odds ratios (ORs) and accompanying 95 % confidence intervals (CIs). Stata version 12.0 was used to perform all statistical analyses. Seven studies consisting of 508 pediatric patients were included in our study. The pooled ORs (studies n = 7) of eradication rates by intention-to-treat and per-protocol analysis in the probiotics group versus the control group were 1.96 (95 % CI 1.28-3.02) and 2.25 (95 % CI 1.41-3.57), respectively. The pooled OR (studies n = 5) of incidence of total side effects was 0.32 (95 % CI 0.13-0.79), with significant heterogeneity observed (I (2) = 71.9 %). CONCLUSION: Probiotics supplementation in triple therapy for H. pyloriinfection may have beneficial effects on eradication and therapy-related side effects, particularly diarrhea, in children.
Authors: B D Gold; R B Colletti; M Abbott; S J Czinn; Y Elitsur; E Hassall; C Macarthur; J Snyder; P M Sherman Journal: J Pediatr Gastroenterol Nutr Date: 2000-11 Impact factor: 2.839
Authors: Cinthia G Goldman; Domingo A Barrado; Norma Balcarce; Eduardo Cueto Rua; Masaru Oshiro; María L Calcagno; Mariana Janjetic; Julián Fuda; Ricardo Weill; María J Salgueiro; Mauro E Valencia; Marcela B Zubillaga; José R Boccio Journal: Nutrition Date: 2006-09-15 Impact factor: 4.008
Authors: F Gottrand; N Kalach; C Spyckerelle; D Guimber; J F Mougenot; P Tounian; C Lenaerts; B Roquelaure; A Lachaux; A Morali; C Dupont; C Maurage; M O Husson; P Barthélemy Journal: J Pediatr Date: 2001-11 Impact factor: 4.406
Authors: Billy Bourke; Peter Ceponis; Naoki Chiba; Steve Czinn; Richard Ferraro; Lori Fischbach; Ben Gold; Hien Hyunh; Kevan Jacobson; Nicola L Jones; Sibylle Koletzko; Sylvie Lebel; Paul Moayyedi; Robert Ridell; Philip Sherman; Sander van Zanten; Ivan Beck; Linda Best; Margaret Boland; Ford Bursey; Hugh Chaun; Geraldine Cooper; Brian Craig; Carole Creuzenet; Jeffrey Critch; Krishnasamy Govender; Eric Hassall; Alan Kaplan; Monica Keelan; Garth Noad; Marli Robertson; Lesley Smith; Markus Stein; Diane Taylor; Thomas Walters; Robin Persaud; Scott Whitaker; Robert Woodland Journal: Can J Gastroenterol Date: 2005-07 Impact factor: 3.522
Authors: E Lionetti; V L Miniello; S P Castellaneta; A M Magistá; A de Canio; G Maurogiovanni; E Ierardi; L Cavallo; R Francavilla Journal: Aliment Pharmacol Ther Date: 2006-10-10 Impact factor: 8.171
Authors: G D Bell; K Powell; S M Burridge; A Pallecaros; P H Jones; P W Gant; G Harrison; J E Trowell Journal: Aliment Pharmacol Ther Date: 1992-08 Impact factor: 8.171
Authors: Mariangela Rondanelli; Milena Anna Faliva; Simone Perna; Attilio Giacosa; Gabriella Peroni; Anna Maria Castellazzi Journal: Gut Microbes Date: 2017-07-21